Recently, inhibition of the adenosine-generating enzymes CD39 and CD73 showed anti-tumor immunity through multiple mechanisms, including enhancement of T cell and natural killer- (NK) cell function (33, 34). The gene discussed is ENTPD1; the disease is neoplasm.